By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Biotwitter is great for healthy debates.  The most recent has been on the merits of the hybrid vs.an in-person model.  John Maraganore’s excellent

By Aoife Brennan, CEO of Synlogic Therapeutics, as part of the From The Trenches feature of LifeSciVC Earlier this month, I attended the J.P. Morgan 41st annual Healthcare Conference in San Francisco after a two-year hiatus. Despite the torrential rain

Today we’re thrilled to announce the acquisition of Nimbus’ allosteric Tyk2 autoimmune program by Takeda for up to $6 billion in an upfront and future milestones. As a potential best-in-class asset in the significant new therapeutic category of selective Tyk2

By Gerry Harriman and Jonathan Montagu, CSO and CEO, respectively, and co-founders of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC. HotSpot Therapeutics today announced a strategic collaboration with Abbvie to develop IRF5 transcription factor inhibitors

By Ivana Magovčević-Liebisch PhD, JD, CEO of VIGIL NEUROSCIENCE, as part of the From The Trenches feature of LifeSciVC Compared to most industries, biotech life cycles are lengthy. From R&D and clinical development to regulatory approval, it takes an average

We just held our 2022 Annual General Meeting for our investors, and a few weeks ago convened our Atlas Venture Retreat – both in person for the first time in 3 years.  Kicking off each of these meetings is our

By Robert Clarke, CEO and founder of Kinaset Therapeutics, as part of the From The Trenches feature of LifeSciVC 2022 has been a hallmark year for Kinaset Therapeutics as we’ve continued to advance our P1b trial with our lead asset.

By Deanna Petersen, CBO of AVROBio, as part of the From the Trenches feature of LifeSciVC Gene therapy’s tremendous potential to transform the treatment of both rare and common diseases has been understood for decades. But few may appreciate how

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Biotechnology, especially of late, requires us to prevail over adversity to deliver for patients.  Spero, dedicated to new solutions for patients with infections,

By Rene Russo, CEO of Xilio Therapeutics, as part of the From The Trenches feature of LifeSciVC As one thinks about the iconic break-up lines, it doesn’t take long to come up with: It’s not you; it’s me… I am

By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC By all accounts, 2022 did not start according to plan for the biotech industry. The U.S. economy and growth stocks struggled with the

By Peter Smith, co-founder and CEO, Remix Therapeutics, as part of the From The Trenches feature of LifeSciVC One of the joys of starting a company is the ability to pro-actively define the early corporate culture and encourage its evolution